BRAF and neoplasm: A novel TRIM22-BRAF fusion was identified in both histologies of the tumor, with EnFusion results from the ganglioglioma portion represented in Fig. 5A. TRIM22-BRAF was the only consensus fusion output by EnFusion and was clinically confirmed by RT-PCR.